Tramadol and O-desmethyltramadol Fixed-Ratio Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tramadol analgesia is ineffective in individuals with reduced CYP2D6 activity, known as poor metabolizers, due to insufficient production of its metabolite O-desmethyltramadol, leading to resistance and adverse events, while ultra-rapid metabolizers experience excessive adverse effects.
Innovation Solution
A pharmaceutical composition comprising a synergistic combination of O-desmethyltramadol and tramadol, administered together in specific ratios and forms, such as sustained release and immediate release, to maintain optimal blood plasma levels and concentration ratios, overcoming resistance and adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tramadol is administered alone, then analgesic activity is achieved in extensive metabolizers, but resistance occurs in poor metabolizers due to insufficient O-desmethyltramadol production
Solution Approach 1:
The patent combines tramadol and its active metabolite O-desmethyltramadol into a single pharmaceutical composition. This merging approach ensures that poor metabolizers receive both the parent compound and the active metabolite directly, while extensive metabolizers receive the synergistic combination, thereby resolving the contradiction between maintaining reliability in EMs and achieving adaptability across different phenotypes.
Solution Approach 2:
The patent changes the pharmacokinetic parameters by providing fixed ratios of tramadol to O-desmethyltramadol (e.g., 1:1, 1:2, 1:3). This parameter change ensures that poor metabolizers achieve therapeutic levels of the active metabolite without relying on CYP2D6 conversion, while extensive metabolizers receive optimized dosing that prevents accumulation and adverse events.
2Reliability
If tramadol is administered in standard doses, then adequate analgesia is provided in poor metabolizers, but adverse events increase in ultra-rapid metabolizers due to excessive O-desmethyltramadol production
Solution Approach 1:
The patent implements precise parameter control by establishing fixed ratios of tramadol to O-desmethyltramadol in the pharmaceutical composition. This ensures that ultra-rapid metabolizers receive a controlled amount of the active metabolite that prevents excessive accumulation and associated adverse events, while poor metabolizers receive sufficient O-desmethyltramadol to achieve adequate analgesia.
Solution Approach 2:
The patent uses O-desmethyltramadol as an intermediary substance that mediates the analgesic effect. By including this metabolite directly in the composition, the patent bypasses the need for CYP2D6-mediated conversion, thereby eliminating the harmful variability in metabolite production across different phenotypes and resolving the contradiction between efficacy in PMs and safety in UMs.
3Adaptability or versatility
If only tramadol is used, then the drug maintains unscheduled status and lower dependence risk, but analgesic activity is insufficient in poor metabolizers
Solution Approach 1:
The patent merges tramadol with O-desmethyltramadol in a fixed-ratio combination, creating a composition that ensures adequate analgesic activity in poor metabolizers who cannot convert tramadol to the active metabolite. This merging maintains the favorable safety profile and unscheduled status of tramadol while resolving the efficacy issue in PMs through the inclusion of the active metabolite.
4Reliability
If O-desmethyltramadol is administered alone, then effective analgesia is achieved in poor metabolizers, but the synergistic opioid and monoaminergic activity is not fully restored
Solution Approach 1:
The patent combines tramadol and O-desmethyltramadol to restore the complete spectrum of analgesic activity. Tramadol contributes both opioid receptor binding and monoaminergic reuptake inhibition, while O-desmethyltramadol provides enhanced opioid activity. This merging ensures that poor metabolizers receive the full synergistic effect that would normally result from complete CYP2D6 conversion, thereby resolving the contradiction between efficacy and restoration of synergistic activity.
Data Source
AI summary
There is disclosed a composition for oral administration of O-desmethyltramadol. Compositions are also provided that are effective for overcoming resistance to tramadol in patients.